Prima BioMed (PBMD) Getting Somewhat Favorable Press Coverage, Accern Reports

Media headlines about Prima BioMed (NASDAQ:PBMD) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Prima BioMed earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.787579837059 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Prima BioMed (NASDAQ PBMD) opened at 2.2001 on Wednesday. The company’s market cap is $51.88 million. The company has a 50 day moving average price of $2.04 and a 200 day moving average price of $2.06. Prima BioMed has a one year low of $1.40 and a one year high of $3.26.

Separately, Maxim Group set a $7.00 price objective on Prima BioMed and gave the stock a “buy” rating in a report on Wednesday, July 19th.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.com-unik.info/2017/11/01/prima-biomed-pbmd-getting-somewhat-favorable-press-coverage-accern-reports.html.

Prima BioMed Company Profile

Prima BioMed Ltd is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.

Insider Buying and Selling by Quarter for Prima BioMed (NASDAQ:PBMD)

What are top analysts saying about Prima BioMed Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Prima BioMed Ltd and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit